XML 27 R15.htm IDEA: XBRL DOCUMENT v3.26.1
Revenues
 3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Product Revenue, Net
The Company’s product revenue is derived from the sales of its commercial products in Greater China. The table below presents the Company’s gross and net product revenue ($ in thousands):
Three Months Ended March 31,
20262025
Product revenue - gross102,254 112,333 
Less: Rebates and sales returns(6,698)(6,683)
Product revenue - net95,556 105,650 
Sales rebates are offered to distributors in mainland China, and the amounts are recorded as a reduction of product revenue. Estimated rebates are determined based on contracted rates, sales volumes, and level of distributor inventories.
The following table presents the Company’s net revenue by commercial program ($ in thousands):
Three Months Ended March 31,
20262025
ZEJULA29,967 49,529 
VYVGART / VYVGART Hytrulo17,551 18,105 
NUZYRA16,262 15,118 
OPTUNE12,070 11,363 
QINLOCK8,985 8,509 
XACDURO8,572 1,117 
AUGTYRO1,792 1,626 
Other (i)357 283 
Product revenue - net95,556 105,650 
(i)Other includes product candidates sold in patient programs prior to commercialization.
Collaboration Revenue
Collaboration revenue was $4.1 million and $0.8 million in the first quarter of 2026 and 2025, respectively, and mainly related to a regional license and collaboration arrangement and promotional activities in mainland China.